Outcomes of fludarabine‐melphalan versus fludarabine‐busulfan reduced‐intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta‐analysis
Cancer · 15.12.2025 · 131 (24)
DOI: 10.1002/cncr.70199 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cancer, online erschienen am 06.12.2025. Verfasst von Chalothorn Wannaphut und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA. Hauptthemen laut MEDLINE: Busulfan, Hematologic Neoplasms, Vidarabine, Transplantation Conditioning. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Fludarabine with melphalan (FM) or busulfan (FB) is among the most widely used reduced‐intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation (allo‐HSCT). The authors conducted a systematic review and meta‐analysis comparing these regimens in adult patients with hematologic malignancies.
Methods
A comprehensive search of Ovid MEDLINE, Embase, and the Cochrane Library from inception through July 22, 2025, identified 17 eligible studies involving 10,396 patients. Pooled analyses were performed using a random‐effects model, and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated.
Results
In the overall analysis, FM was associated with improved progression‐free survival (PFS) (HR, 0.90; 95% CI, 0.82–0.98), driven by lower relapse rates (HR, 0.69; 95% CI, 0.62–0.78) but increased treatment‐related mortality (TRM) (HR, 1.44; 95% CI, 1.10–1.89). There were no significant differences in overall survival (OS), grade 3–4 acute graft‐versus‐host disease (GVHD), or chronic GVHD. In subgroup analyses, FM significantly improved OS and PFS, primarily driven by a significant reduction in relapse risk in acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) and elderly patients aged ≥60 years without significant differences in TRM. In contrast, for lymphoma patients, FM was associated with worse OS and higher TRM compared with FB, and no advantage in PFS, but significantly lower relapse.
Conclusions
These findings suggest that FM may be a preferred reduced‐intensity regimen for AML/MDS and elderly patients, whereas lower intensity regimens may be needed for lymphoma to reduce TRM and optimize long‐term survival after allo‐HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.
- Division of Hematology/Oncology, Department of Medicine, Hematopoietic Stem Cell Transplantation and Cellular Therapy Program, University of California Irvine, Orange, California, USA.
- Division of Hematology, Department of Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand.
ORCID-Profile: Chalothorn Wannaphut, Stefan O Ciurea
Zitieren
APA
Wannaphut, C., Chumnumsiriwath, P., Ciurea, S. O., & Kongtim, P. (2025). Outcomes of fludarabine‐melphalan versus fludarabine‐busulfan reduced‐intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta‐analysis. Cancer, 131(24). https://doi.org/10.1002/cncr.70199
Vancouver
Wannaphut C, Chumnumsiriwath P, Ciurea SO, Kongtim P. Outcomes of fludarabine‐melphalan versus fludarabine‐busulfan reduced‐intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta‐analysis. Cancer. 2025;131(24). doi:10.1002/cncr.70199
BibTeX
@article{Wannaphut2025,
author = {Wannaphut, Chalothorn and Chumnumsiriwath, Piyatida and Ciurea, Stefan O and Kongtim, Piyanuch},
title = {Outcomes of fludarabine‐melphalan versus fludarabine‐busulfan reduced‐intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta‐analysis},
journal = {Cancer},
year = {2025},
volume = {131},
number = {24},
doi = {10.1002/cncr.70199}
}
EUVIMED